文献速递药疹与重症皮肤不良反应皮肤肿瘤

免疫检查点抑制剂引起的皮肤不良事件

Cutaneous adverse events caused by immune checkpoint inhibitors.
PubMed 文献 · J Am Acad Dermatol · 2021-07-28

免疫检查点抑制剂(ICI)已用于多种癌症,皮肤毒性是常见免疫相关不良事件,患者常被转诊至皮肤科。ICI相关皮肤不良事件表现多样,常见湿疹样、麻疹样、苔藓样皮病及白癜风和瘙痒,少见包括银屑病样、大疱性疾病和严重皮肤不良反应。多数对局部或全身激素有反应,但特定毒性可能有替代治疗。

要点

  • ICI皮肤毒性常见表现为湿疹样、麻疹样、苔藓样皮病、白癜风和瘙痒。
  • 少见但需警惕银屑病样、大疱性疾病及SJS/TEN/DRESS等严重反应。
  • ICI可伴风湿性不良反应的皮肤表现,如硬皮病、皮肌炎、皮肤狼疮和血管炎。

核心结论

  • ICI相关皮肤不良事件表现多样,准确诊断和治疗对患者最佳结局至关重要。

研究设计与样本

  • 本文为J Am Acad Dermatol发表的综述,总结ICI所致皮肤不良事件的临床表现、机制和治疗。

主要发现

  • 常见ICI皮肤不良事件包括湿疹样、麻疹样、苔藓样皮病、白癜风和瘙痒。
  • 少见ICI皮肤不良事件包括银屑病样皮病、大疱性疾病和严重皮肤不良反应(SJS、TEN、DRESS)。
  • ICI可伴风湿性不良反应的皮肤表现,如硬皮病、皮肌炎、皮肤红斑狼疮和各种血管炎。
  • ICI皮肤反应常对局部或全身激素有反应,特定毒性可能有替代治疗。

临床怎么用

  • 皮肤科医生应识别ICI相关皮肤不良事件的多样表现,准确诊断并治疗以改善患者结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immune checkpoint inhibitors (ICIs) have emerged as active therapies for a variety of cancers. Cutaneous toxicities are common immune-related adverse events and patients will often be referred to dermatologists for evaluation. OBSERVATIONS: Cutaneous adverse events to ICIs can have a variety of clinical presentations. Among the more common are eczematous, morbilliform, and lichenoid dermatoses, as well as vitiligo and pruritus. Less common adverse events include psoriasiform dermatoses, bullous disorders, and severe cutaneous adverse reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms. Because of the immunologic mechanism of ICIs, there are also a variety of rheumatologic adverse reactions with cutaneous manifestations, such as scleroderma, dermatomyositis, cutaneous lupus erythematosus, and various vasculitides. These cutaneous reactions often respond to topical or systemic steroids, although specific toxicities may have alternative treatments available. CONCLUSIONS AND RELEVANCE: As they become more widely prescribed, dermatologists will see an increasing number of patients with cutaneous adverse events caused by ICI therapies. Accurately diagnosing and treating these toxicities is paramount to achieving the most favorable outcomes for patients.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Quach HT, Johnson DB, LeBoeuf NR, et al. Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol. 2021. PMID: 34332798. doi:10.1016/j.jaad.2020.09.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。